GeNeuro: Availability of Documents and Information for the Annual Shareholders Meeting of May 27, 2021
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
Based on article 27 of Ordinance 3 on Measures to combat the Coronavirus of 19 June 2020 (COVID-19 Ordinance 3, status as of May 1st, 2021), the Board of Directors has decided that shareholders of the Company may exercise their rights at this Ordinary General Meeting exclusively through the Independent Proxy. This measure allows the Company to hold the Ordinary General Meeting as planned despite the pandemic. The conduct of the Ordinary General Meeting remains subject to additional measures issued by the
Financial Summary:
Income remained stable in the first quarter 2021 compared to the first quarter 2020 and related primarily to amounts received under our funded research collaboration with Indivior.
R&D expenses decreased by CHF 0.8 million to CHF 2.7 million in the first quarter 2021 compared to CHF 3.6 million in the first quarter 2020, primarily due to the postponement of the start of our dipraglurant phase 2b/3 PD dyskinesia clinical trial. Research and development expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs. They also include depreciation of laboratory equipment, costs of materials used in research, costs associated with renting and operating facilities and equipment, as well as fees paid to consultants, patent costs and other outside service fees and overhead costs. These expenses include costs for proprietary and third-party R&D.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Increases Issued Share Capital to Create Treasury Shares
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its share capital from 39,748,635 to 49,272,952 through the issue of 9,524,317 new registered shares at a nominal value of CHF1 each to Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s authorized capital, are listed on the SIX Swiss Exchange. The transaction has been executed to provide the Group with additional future financing flexibility.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 4ᵗʰ Annual Neuroscience Innovation Forum (April 26 - 30, 2021).
In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing to registered participants at the forum. Mr Dyer will also be speaking at the Parkinson’s & Movement Disorders Panel scheduled for 13:20 EDT, April 28, 2021.
Audi school’s back
The tenth year of Audi Australia’s local Audi Driving Experience programs will be the biggest yet
Ever wanted to drift an Audi RS 6, carve apexes in an Audi R8 or experience hot hatch heaven in an Audi RS 3?
Your chance to do so is back on the cards with the reinstatement of Audi Australia’s Audi Driving Experience program for 2021.
The global pandemic’s local effects saw the Audi racetrack program forced off-track in 2020. But the gradual opening up of Australian borders and its racetracks has seen the Audi Driving Experience (ADE) back in action for 2021, its tenth year of operation.